RN486

Known as: 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-(1-methyl-5-(5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl)-2H-isoquinolin-1-one 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2015
2015
Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments… (More)
Is this relevant?
2015
2015
A series of pyrrolo[2,3-b]pyridine-based derivatives were designed as potent Bruton's tyrosine kinase (BTK) inhibitors by using a… (More)
Is this relevant?
2015
2015
A series of novel reversible BTK inhibitors was designed based on the structure of the recently reported preclinical drug RN486… (More)
  • figure 1
  • table 1
Is this relevant?
2015
2015
A series of novel reversible Btk inhibitors has been designed based on the structure of the recently reported preclinical drug… (More)
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Is this relevant?
2015
2015
OBJECTIVES Bruton's tyrosine kinase (Btk) is required for B lymphocyte and myeloid cell contributions to pathology in murine… (More)
Is this relevant?
2013
2013
OBJECTIVE Bruton's tyrosine kinase (BTK) plays a critical role in B cell development and function. We recently described a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?